APLMW (Apollomics) Other Current Liabilities : $-0.00 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apollomics Other Current Liabilities?

Apollomics's other current liabilities for the quarter that ended in Jun. 2024 was $-0.00 Mil.

Apollomics's quarterly other current liabilities increased from Jun. 2023 ($-1.00 Mil) to Dec. 2023 ($-0.00 Mil) but then from Dec. 2023 ($-0.00 Mil) to Jun. 2024 ($-0.00 Mil).

Apollomics's annual other current liabilities declined from Dec. 2021 ($0.65 Mil) to Dec. 2022 ($-0.93 Mil) but then increased from Dec. 2022 ($-0.93 Mil) to Dec. 2023 ($-0.00 Mil).

Apollomics Other Current Liabilities Historical Data

The historical data trend for Apollomics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Other Current Liabilities Chart

Apollomics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Apollomics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Current Liabilities	Get a 7-Day Free Trial			-	-	-	-	-

Apollomics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Apollomics Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Apollomics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

APLM:USA

Address

989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404

Website

https://www.apollomicsinc.com

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.